Ryan Specialty Hldgs 株価情報 (NYSE: RYAN)

最新ニュース Ryan Specialty Hldgs (NYSE:RYAN) 株価情報

Ryan Specialty Hldgs

Ryan Specialty Holdings Inc is a service provider of specialty products and solutions for insurance brokers, agents, and carriers. It provides distribution, underwriting, product development, administration, and risk management services by acting as a wholesale broker and a managing underwriter.

Ryan Specialty Holdings, Inc. Class A Common Stock

Ryan Specialty Holdings Inc

Ryanair Holdings plc - American Depositary Shares, each representing five Ordinary Shares

Ryanair Holdings PLC

RYANAIR HLDGS PLC ORD NEW by Ryanair Holdings Plc

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
<h3 class="wp-block-heading">Healthcare Realty Trust Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>)</h3>
<ul>
<li>Dividend Yield: 7.33%</li>
<li>Wedbush analyst Richard Anderson downgraded the stock from Neutral to Underperform and cut the price target from $18 to $16 on Jan. 2, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Wells Fargo analyst James Feldman assumed an Underweight rating and increased the price target from $16 to $17 on Oct. 1, 2024. This analyst has an accuracy rate of 60%.</li>
<li>Recent News: On Feb. 19, Healthcare Realty Trust reported quarterly earnings of 40 cents per share.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1">HR news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="897" height="397" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142718/image-208.png" alt="" class="wp-image-798244" style="width:517px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142718/image-208.png 897w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142718/image-208-300x133.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142718/image-208-768x340.png 768w" sizes="(max-width: 897px) 100vw, 897px" /></a></figure>
<h3 class="wp-block-heading">Omega Healthcare Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>)</h3>
<ul>
<li>Dividend Yield: 7.27%</li>
<li>JMP Securities analyst Aaron Hecht reiterated a Market Perform rating on Feb. 7, 2025. This analyst has an accuracy rate of 60%.</li>
<li>RBC Capital analyst Michael Carroll maintained a Sector Perform rating and raised the price target from $39 to $43 on Nov. 11, 2024. This analyst has an accuracy rate of 63%.</li>
<li>Recent News: On Feb. 5, the company posted upbeat quarterly sales.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1">OHI news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="806" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25143021/image-211.png" alt="" class="wp-image-798252" style="width:634px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25143021/image-211.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25143021/image-211-300x266.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25143021/image-211-768x682.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">EPR Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>)</h3>
<ul>
<li>Dividend Yield: 6.75%</li>
<li>JP Morgan analyst Anthony Paolone maintained an Overweight rating and increased the price target from $48 to $51 on Sept. 9, 2024. This analyst has an accuracy rate of 64%.</li>
<li>Truist Securities analyst Ki Bin Kim maintained a Hold rating and boosted the price target from $44 to $46 on Aug. 16, 2024. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On Jan. 27, EPR Properties elected John Peter (JP) Suarez to its Board of Trustees.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1">latest EPR news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="807" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142824/image-210.png" alt="" class="wp-image-798248" style="width:506px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142824/image-210.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142824/image-210-300x267.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142824/image-210-768x683.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43937701/how-to-earn-500-a-month-from-lowes-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Lowe&#8217;s Stock Ahead Of Q4 Earnings</a></li>
</ul>

Earnings

News

Dividends

Price Target

Markets

Analyst Ratings

Trading Ideas

Wall Street's Most Accurate Analysts Spotlight On 3 Real Estate Stocks With Over 6% Dividend Yields

Financial giants have made a conspicuous bullish move on Atlassian. Our analysis of options history for Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) revealed 17 unusual trades.
Delving into the details, we found 58% of traders were bullish, while 23% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $330,440, and 11 were calls, valued at $460,378.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $275.0 to $370.0 for Atlassian over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Atlassian's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Atlassian's whale trades within a strike price range from $275.0 to $370.0 in the last 30 days. 
<h3>Atlassian 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740511869_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEAM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$9.3</td>
<td>$6.3</td>
<td>$8.1</td>
<td>$370.00</td>
<td>$81.0K</td>
<td align="right">116</td>
<td align="right">100</td>
</tr>
<tr>
<td>TEAM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$7.8</td>
<td>$7.0</td>
<td>$7.0</td>
<td>$280.00</td>
<td>$70.0K</td>
<td align="right">194</td>
<td align="right">329</td>
</tr>
<tr>
<td>TEAM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$11.9</td>
<td>$11.1</td>
<td>$11.4</td>
<td>$285.00</td>
<td>$67.2K</td>
<td align="right">6</td>
<td align="right">60</td>
</tr>
<tr>
<td>TEAM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/07/25</td>
<td>$6.5</td>
<td>$5.4</td>
<td>$6.3</td>
<td>$280.00</td>
<td>$63.0K</td>
<td align="right">11</td>
<td align="right">0</td>
</tr>
<tr>
<td>TEAM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$6.6</td>
<td>$6.2</td>
<td>$6.3</td>
<td>$275.00</td>
<td>$60.4K</td>
<td align="right">214</td>
<td align="right">102</td>
</tr>
</tbody>
</table>

<h3>About Atlassian</h3>
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Following our analysis of the options activities associated with Atlassian, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Atlassian</h3>
<ul>
<li>Currently trading with a volume of 820,195, the TEAM's price is down by -0.19%, now at $283.53. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 58 days.</li>
</ul>
<h3>Professional Analyst Ratings for Atlassian</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $348.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Atlassian, which currently sits at a price target of $350. 
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Atlassian, maintaining a target price of $380. 
&#x2A; An analyst from UBS has decided to maintain their Neutral rating on Atlassian, which currently sits at a price target of $330. 
&#x2A; An analyst from Macquarie persists with their Neutral rating on Atlassian, maintaining a target price of $317. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Atlassian, maintaining a target price of $365. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Atlassian options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

TEAM

Decoding Atlassian's Options Activity: What's the Big Picture?

Investors with a lot of money to spend have taken a bullish stance on Coupang (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CPNG, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Coupang.
This isn't normal.
The overall sentiment of these big-money traders is split between 53% bullish and 33%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $165,024, and 12 are calls, for a total amount of $985,598.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $21.0 to $30.0 for Coupang over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Coupang stands at 4837.64, with a total volume reaching 18,661.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Coupang, situated within the strike price corridor from $21.0 to $30.0, throughout the last 30 days.
<h3>Coupang Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740511864_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$0.56</td>
<td>$0.52</td>
<td>$0.54</td>
<td>$25.50</td>
<td>$323.0K</td>
<td>3.8K</td>
<td>7.2K</td>
</tr>
<tr>
<td>CPNG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$0.85</td>
<td>$0.8</td>
<td>$0.84</td>
<td>$25.00</td>
<td>$159.2K</td>
<td>16.6K</td>
<td>2.7K</td>
</tr>
<tr>
<td>CPNG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.27</td>
<td>$1.24</td>
<td>$1.27</td>
<td>$24.00</td>
<td>$113.7K</td>
<td>1.9K</td>
<td>1.1K</td>
</tr>
<tr>
<td>CPNG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.33</td>
<td>$1.26</td>
<td>$1.29</td>
<td>$24.00</td>
<td>$86.8K</td>
<td>1.8K</td>
<td>672</td>
</tr>
<tr>
<td>CPNG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$1.64</td>
<td>$1.57</td>
<td>$1.63</td>
<td>$27.00</td>
<td>$65.3K</td>
<td>46</td>
<td>401</td>
</tr>
</tbody>
</table>

<h3>About Coupang</h3>
Coupang is South Korea's largest e-commerce platform that sells both owned and third-party inventory. Headquartered in the us, Coupang operates e-commerce businesses mainly in South Korea and Taiwan. The company has built an integrated logistics network that covers the entirety of South Korea, with extensive fulfillment centers that ensure timely delivery, even for orders placed seconds before midnight. Outside of its bread-and-butter e-commerce business, Coupang has expanded into provision of its Rocket delivery services to third-party merchants (fulfillment and logistics by Coupang), online grocery delivery Rocket Fresh, online meal delivery (Eats), e-commerce in Taiwan, luxury e-commerce (Farfetch), and travel.
<h3>Coupang's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 11,584,464, the CPNG's price is down by -2.01%, now at $24.14. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 0 days.</li>
</ul>
<h3>What The Experts Say On Coupang</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $34.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Coupang, maintaining a target price of $34. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Coupang, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

CPNG

Coupang Unusual Options Activity For February 25

Financial giants have made a conspicuous bullish move on Axon Enterprise. Our analysis of options history for Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) revealed 78 unusual trades.
Delving into the details, we found 46% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 51 were puts, with a value of $2,873,976, and 27 were calls, valued at $1,384,244.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $100.0 to $720.0 for Axon Enterprise over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Axon Enterprise stands at 176.14, with a total volume reaching 5,797.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Axon Enterprise, situated within the strike price corridor from $100.0 to $720.0, throughout the last 30 days.
<h3>Axon Enterprise Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740511859_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$25.2</td>
<td>$22.6</td>
<td>$24.0</td>
<td>$600.00</td>
<td>$251.9K</td>
<td align="right">210</td>
<td align="right">0</td>
</tr>
<tr>
<td>AXON</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$37.0</td>
<td>$35.1</td>
<td>$35.8</td>
<td>$490.00</td>
<td>$164.6K</td>
<td align="right">471</td>
<td align="right">239</td>
</tr>
<tr>
<td>AXON</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$71.8</td>
<td>$68.8</td>
<td>$70.63</td>
<td>$540.00</td>
<td>$148.3K</td>
<td align="right">338</td>
<td align="right">97</td>
</tr>
<tr>
<td>AXON</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$86.8</td>
<td>$83.7</td>
<td>$86.8</td>
<td>$560.00</td>
<td>$130.2K</td>
<td align="right">504</td>
<td align="right">26</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$24.8</td>
<td>$23.3</td>
<td>$24.2</td>
<td>$540.00</td>
<td>$121.0K</td>
<td align="right">172</td>
<td align="right">112</td>
</tr>
</tbody>
</table>

<h3>About Axon Enterprise</h3>
Axon Enterprise Inc develops, manufactures, and sells conducted energy devices and cloud-based digital evidence management software designed for use by law enforcement, corrections, military forces, private security personnel, and private individuals for personal defense. The company operates in two segments: Taser and software &amp; sensors. Taser develops and sells CEDs used for protecting users and virtual reality training. Software and sensors manufacture fully integrated hardware and cloud-based software solutions such as body cameras, automated license plate reading, and digital evidence management systems. Axon delivers its products worldwide and derives the majority of its revenue from the software &amp; sensors segment and geographically from the United States.
<h3>Where Is Axon Enterprise Standing Right Now?</h3>
<ul>
<li>With a trading volume of 687,548, the price of AXON is down by -0.44%, reaching $497.52.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 0 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Axon Enterprise</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $683.33.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Buy rating for Axon Enterprise, targeting a price of $700. 
&#x2A; An analyst from Craig-Hallum has revised its rating downward to Hold, adjusting the price target to $625. 
&#x2A; Consistent in their evaluation, an analyst from JMP Securities keeps a Market Outperform rating on Axon Enterprise with a target price of $725. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Axon Enterprise with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

AXON

A Closer Look at Axon Enterprise's Options Market Dynamics

Tesla Automation GmbH, a subsidiary of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), has reached an <a target="_blank" href="https://www.manz.com/en/company/news/manz-ag-opening-of-insolvency-proceedings/" rel="noreferrer noopener">agreement to purchase assets </a>from the German technology company Manz AG.
According to the press release issued on Tuesday, the deal involves acquiring Manz's Reutlingen facility along with over 300 employees working there. Tesla Automation plans to manage this new location moving forward.
The transaction is awaiting clearance from the German Federal Cartel Office under antitrust regulations, and the purchase price has not been revealed.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43932533/tesla-starts-rolling-out-fsd-features-in-china" rel="noreferrer noopener">Tesla Starts Rolling Out FSD Features In China A Month After Elon Musk Said EV Giant Faces' Challenges' In The Country</a>
Manz AG has initiated insolvency proceedings following a ruling by the Local Court of Stuttgart on 24 February 2025. As part of the insolvency process, the company will cease operations and liquidate its assets. Job losses will affect approximately 100 employees.
Those not moving to Tesla Automation will be provided opportunities through a transfer company to help ease the transition.
"We are gaining qualified employees with a high level of expertise in high-tech mechanical engineering. The Reutlingen site is an ideal complement to the continued successful implementation of our global automation projects in the Tesla Group. We are very pleased to be realizing future innovations there," said Managing Director at Tesla Automation, Lothar Thommes.
Manz AG had announced earlier, in January 2025, that it would seek to sell all of its business units. In addition to the Reutlingen site, various subsidiaries are part of the ongoing sales process.
Although the asset sale is underway, it is anticipated that the proceeds will not fully satisfy the claims of non-subordinated creditors, and no payments will be made to subordinated creditors, including shareholders.
Manz AG specializes in creating production solutions for lithium-ion batteries and electronic components, serving industries such as automotive and e-mobility, electronics, energy, and battery manufacturing.
Employing approximately 1,200 people, the Manz Group operates production facilities in Germany, Slovakia, Italy, mainland China, and Taiwan, with additional sales and service offices in the USA and India.
Tesla reported fourth-quarter <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43321103/tesla-q4-earnings-highlights-revenue-miss-eps-miss-ev-updates-automaker-says-2025-will-be-a-seminal-year" rel="noreferrer noopener">revenue of $25.71 billion</a>, up 2% year-over-year. Automotive revenue totaled $19.8 billion in the fourth quarter, down 8% year-over-year.
Price Action: TSLA shares are trading lower by 9.74% at $298.05 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43937036/david-imai-leaves-tesla-design-team-within-months-of-bernard-lee" target="_blank" rel="noreferrer noopener">Elon Musk-Led Tesla Loses Another Key Designer As David Imai Heads To Arc Boats</a></li>
</ul>
Image via brichuas and Felix Mizioznikov on Shutterstock

Tech

General

TSLA

Tesla Acquires German Tech Firm Manz Assets Amid Insolvency

WIIM

Home Depot shares are trading higher after the company reported better-than-expected Q4 financial results and raised its quarterly dividend.

JPMorgan analyst Bryan M. Smilek reiterated a <a href="https://www.benzinga.com/quote/CHGG/analyst-ratings">Neutral rating</a> on the shares of Chegg Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>)
The company struggles with both long-term challenges and increased competition, leading to a weaker-than-expected outlook for first-quarter, said the analyst. 
Chegg revealed it is undergoing a strategic review and considering various options, including a potential acquisition, a go-private deal, or staying as an independent public company.
The <a href="https://www.benzinga.com/news/earnings/25/02/43927381/chegg-stock-plunges-after-q4-revenue-falls-24-weak-q1-guidance-details">first-quarter revenue</a> forecast suggests a decline of 33%-35% year-over-year, with the company attributing the drop to competition from generative AI and large language models, particularly due to Google&#8217;s widespread rollout of AI-driven overviews.
In January, Chegg's global non-subscriber traffic plummeted by 49% compared to the previous year, while retention rates worsened during November and December.
Churn improved toward the end of December and has since stabilized in first quarter. Chegg believes the traffic decline is mainly due to Google's AI Overviews diverting users away from third-party websites, prompting Chegg to file a complaint against Google and its parent company, Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>).
The complaint alleges that Google forces Chegg to provide proprietary content for its search engine, misuses its monopoly power in search and benefits from Chegg's content without compensating it.
Also Read: <a href="https://www.benzinga.com/news/management/25/02/43946567/unilever-ceo-hein-schumacher-to-step-down-fernando-fernandez-to-take-over">Unilever CEO Hein Schumacher To Step Down, Fernando Fernandez To Take Over</a>
Amid these challenges, Chegg is focused on stabilizing its business through product improvements, diversifying its marketing efforts, and growing its Enterprise/Busuu segment. 
The company acknowledges rebuilding its subscriber base and improving top-of-funnel metrics will take time, noted the analyst.
The company is also working on cost reductions and expects to achieve $100 million to $120 million in annualized non-GAAP savings by 2025 from restructuring efforts.
Despite these pressures, Chegg is committed to balancing investments in growth, profitability, debt repayments and shareholder returns, including a $207.5 million buyback authorization.
Notably, Chegg's $358.6 million in 2025 convertible senior notes will mature on March 15. While industry challenges are expected to persist into 2025, Chegg is hopeful subscriber and revenue trends will stabilize later in the year and the company will manage expenses to preserve profitability.
In light of these difficulties, the analyst reduced 2025 and 2026 revenue estimates by approximately 15% and adjusted EBITDA by 50%-56%.
The company believes enhancing its products, expanding marketing efforts and driving enterprise growth will help revive subscriber and revenue growth, though the timeline for this recovery is uncertain, the analyst wrote.
CHGG Price Action: Chegg shares are trading lower by 28.85% at $1.11 at publication Tuesday.
Read Next: • <a href="https://www.benzinga.com/25/02/43911212/tiktok-collaboration-powers-connexas-new-mena-strategy-stocks-skyrocket">TikTok Collaboration Powers Connexa&#8217;s New MENA Strate</a> Photo via Shutterstock

Reiteration

CHGG

GOOG

GOOGL

Chegg Struggles With Declining Traffic, Revenue Amid Increased Competition, Says Analyst

Italy&#8217;s government is considering replacing&nbsp;STMicroelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) chief Jean-Marc Chéry after he failed to improve <a target="_blank" href="https://www.benzinga.com/topic/chip-stocks" rel="noreferrer noopener">the company&#8217;s prospects</a>.
Rome considers the CEO&#8217;s performance insufficient, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-02-25/italy-said-to-seek-removal-of-stmicro-ceo-on-poor-performance?sref=TBDibEcD" rel="noreferrer noopener">reported</a>, citing unnamed sources familiar with the matter. Italian officials told Bloomberg they may lack the instruments to provide a replacement.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/25/02/43939199/alibaba-doubles-down-on-ai-launches-qwq-max-to-challenge-openai-and-deepseek" rel="noreferrer noopener">Alibaba Doubles Down On AI, Launches QwQ-Max to Challenge OpenAI and DeepSeek</a>
Rome and Paris governments hold a combined 27.8% stake in the company, according to Bloomberg data. Chéry was reelected for a three-year term in May last year.
Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)&nbsp;and&nbsp;Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) supplier STMicroelectronics stock plunged 30% in the last 12 months as it struggled to navigate a slump in demand for automobile and industrial semiconductors.
STMicroelectronics reported fourth-quarter net revenues of $3.32 billion, down by 22.4%, beating the&nbsp;analyst estimate of $3.31 billion. EPS of $0.37&nbsp;missed&nbsp;the&nbsp;consensus estimate of $0.38.
At the mid-point, STMicroelectronics expects <a target="_blank" href="https://www.benzinga.com/25/01/43334149/stmicroelectronics-q4-earnings-22-revenue-drop-sees-challenges-ahead-with-lower-industrial-and-auto-demand" rel="noreferrer noopener">fiscal&nbsp;first-quarter</a> net revenues&nbsp;to be&nbsp;$2.51 billion, a decrease of&nbsp;24.4%&nbsp;sequentially, plus or minus 350 basis points versus&nbsp;the $2.76 billion consensus estimate.
The company said in January that 2024 was one of the worst years in decades for the industry. It was reportedly looking to cut up <a target="_blank" href="https://www.benzinga.com/media/25/01/43399736/apple-and-tesla-supplier-stmicroelectronics-plans-up-to-3000-job-cuts-in-italy-and-france" rel="noreferrer noopener">to 3,000 jobs</a>.
Last year, the Intel board fired CEO Pat Gelsinger after his <a target="_blank" href="https://www.benzinga.com/25/01/43065280/intel-gains-8-on-speculation-of-buyout-details-remain-unclear" rel="noreferrer noopener">turnaround efforts failed</a> to materialize. CFO Dave Zinsner and Michelle Johnston Holthaus became&nbsp;Intel&#8217;s interim co-CEOs.&nbsp;
Price Action: STM stock traded lower by&nbsp;1.86%&nbsp;to&nbsp;$26.90 at&nbsp;the last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/02/43938789/intel-deploys-asmls-advanced-euv-machines-aims-to-challenge-taiwan-semiconductors-lead" target="_blank" rel="noreferrer noopener">Intel Deploys ASML&#8217;s Advanced EUV Machines, Aims to Challenge Taiwan Semiconductor&#8217;s Lead</a></li>
</ul>
Photo by Michael Vi via Shutterstock

Eurozone

Management

Media

AAPL

STMicroelectronics Faces Leadership Shakeup, Italy Seeks New CEO Amid Semiconductor Struggles

On Monday, in its earnings release, Myriad Genetics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) said Unitedhealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) UnitedHealthcare will stop covering multi-gene panel pharmacogenetic testing, including Myriad Genetics&#8217; GeneSight test, for its commercial, individual exchange, and certain managed Medicaid plans. This change takes effect <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43925676/myriad-genetics-reports-fourth-quarter-and-full-year-2024-financial-results-full-year-2024-revenue" rel="noreferrer noopener">in the first half of 2025</a>.
In 2024, Myriad Genetics earned about $45 million from GeneSight testing through UnitedHealthcare, with $40 million from commercial plans and $5 million from managed Medicaid plans.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43879859/doj-investigates-unitedhealth-probe-accuses-of-inflating-medicare-diagnoses" rel="noreferrer noopener">DOJ Investigates UnitedHealth, Probe Accuses Of Inflating Medicare Diagnoses</a>
While Myriad Genetics continues to pursue a resolution with UnitedHealthcare that allows its commercial and managed Medicaid enrollees to continue accessing the GeneSight test, there is no guarantee that these efforts will succeed. Accordingly, Myriad has streamlined operations and cost structure.
Myriad Genetics also reported:
<ul>
<li>Fourth-quarter adjusted EPS of 3 cents, down from 4 cents a year ago, in line with the consensus.</li>
<li>Fourth-quarter sales of $210.6 million — up 7% year over year, missing the consensus of $211.62 million.</li>
<li>The Oncology business delivered revenue of $82.8 million in the fourth quarter of 2024. </li>
<li>Hereditary cancer testing revenue in Oncology grew 8% year-over-year.</li>
<li>Women's Health business delivered revenue of $87.2 million, and prenatal testing revenue grew 12% year-over-year.</li>
</ul>
Guidance: Myriad Genetics reaffirms 2025 adjusted EPS guidance of 7-11 cents compared to the consensus of 6 cents.
The company expects sales of $840 million-$860 million versus a consensus of $866.2 million.
CEO Change: Myriad Genetics appointed Sam Raha, the company&#8217;s current Chief Operating Officer, as President, CEO, and board member, <a href="https://www.benzinga.com/pressreleases/25/02/g43925648/myriad-genetics-announces-senior-leadership-transition" target="_blank" rel="noreferrer noopener">effective April 30</a>.
Raha will replace Paul J. Diaz, who is stepping down to join private equity firm Cressey &amp; Company.
Analyst Reactions:
<ul>
<li>JPMorgan writes that the fourth quarter miss was driven by softer volumes due to the focus on the launch of Prequel at 8 weeks gestational age and slower order activity among new EMR accounts.</li>
<li>JPMorgan analyst Rachel Vatnsda writes that while the company&#8217;s progress on its recovery plan is promising, there is uncertainty about its long-term growth strategy beyond selling assets. Therefore, JP Morgan <a href="https://www.benzinga.com/quote/MYGN/analyst-ratings" target="_blank" rel="noreferrer noopener">maintains the Underweight rating</a>.</li>
<li>UBS analyst Lu Li maintains Myriad Genetics with a Neutral and lowers the price target from $18 to $16.</li>
</ul>
Price Action: Myriad Genetics stock is down 14.2% at $11.83 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/43943266/diagnostic-company-veracyte-weighs-sale-for-french-subsidiary-analyst-says-walking-away-is-a-long-term-positive" target="_blank" rel="noreferrer noopener">Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says &#8216;Walking Away&#8217; Is A Long-Term Positive</a></li>
</ul>

Analyst Color

Guidance

Health Care

Movers

MYGN

Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO

CTLP

Cantaloupe Shares Resumed Trade

<a href="https://www.bloomberg.com/news/articles/2025-02-25/warner-bros-shuts-three-video-game-studios-in-restructuring?cmpid=socialflow-twitter-business&amp;utm_content=business&amp;utm_campaign=socialflow-organic&amp;utm_source=twitter&amp;utm_medium=social" title="https://www.bloomberg.com/news/articles/2025-02-25/warner-bros-shuts-three-video-game-studios-in-restructuring?cmpid=socialflow-twitter-business&amp;utm_content=business&amp;utm_campaign=socialflow-organic&amp;utm_source=twitter&amp;utm_medium=social">https://www.bloomberg.com/news/articles/2025-02-25/warner-bros-shuts-three-video-game-studios-in-restructuring?cmpid=socialflow-twitter-business&amp;utm_content=business&amp;utm_campaign=socialflow-organic&amp;utm_source=twitter&amp;utm_medium=social</a>

'Warner Bros. Shuts Three Video-Game Studios in Restructuring' - Bloomberg

Asset Sales

Cantaloupe Working With Bankers At JPMorgan Chase To Explore Options, Including Sale

Deep-pocketed investors have adopted a bullish approach towards United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in UAL usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 30 extraordinary options activities for United Airlines Holdings. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 60% leaning bullish and 33% bearish. Among these notable options, 10 are puts, totaling $1,119,994, and 20 are calls, amounting to $1,752,676.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $45.0 to $130.0 for United Airlines Holdings over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for United Airlines Holdings's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of United Airlines Holdings's whale trades within a strike price range from $45.0 to $130.0 in the last 30 days. 
<h3>United Airlines Holdings Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740510957_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$10.85</td>
<td>$10.6</td>
<td>$10.64</td>
<td>$100.00</td>
<td>$532.0K</td>
<td>2.9K</td>
<td>600</td>
</tr>
<tr>
<td>UAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$9.7</td>
<td>$9.6</td>
<td>$9.7</td>
<td>$120.00</td>
<td>$244.3K</td>
<td>945</td>
<td>265</td>
</tr>
<tr>
<td>UAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$10.6</td>
<td>$10.5</td>
<td>$10.6</td>
<td>$100.00</td>
<td>$228.9K</td>
<td>2.9K</td>
<td>816</td>
</tr>
<tr>
<td>UAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.4</td>
<td>$5.2</td>
<td>$5.4</td>
<td>$95.00</td>
<td>$216.2K</td>
<td>993</td>
<td>410</td>
</tr>
<tr>
<td>UAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.75</td>
<td>$5.55</td>
<td>$5.75</td>
<td>$95.00</td>
<td>$197.2K</td>
<td>993</td>
<td>1.5K</td>
</tr>
</tbody>
</table>

<h3>About United Airlines Holdings</h3>
United Airlines is a major us network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel than its large us peers.
Following our analysis of the options activities associated with United Airlines Holdings, we pivot to a closer look at the company's own performance.
<h3>Where Is United Airlines Holdings Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 3,986,493, the UAL's price is up by 0.15%, now at $97.92. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 49 days.</li>
</ul>
<h3>What The Experts Say On United Airlines Holdings</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $130.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Susquehanna continues to hold a Positive rating for United Airlines Holdings, targeting a price of $130. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for United Airlines Holdings with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

United Airlines Holdings's Options Frenzy: What You Need to Know

Deep-pocketed investors have adopted a bullish approach towards American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AXP usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for American Express. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 55% leaning bullish and 22% bearish. Among these notable options, 3 are puts, totaling $472,204, and 6 are calls, amounting to $491,612.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $220.0 to $350.0 for American Express over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for American Express's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of American Express's whale trades within a strike price range from $220.0 to $350.0 in the last 30 days. 
<h3>American Express Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740510952_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AXP</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$12.4</td>
<td>$11.3</td>
<td>$11.5</td>
<td>$220.00</td>
<td>$230.0K</td>
<td align="right">133</td>
<td align="right">200</td>
</tr>
<tr>
<td>AXP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$49.1</td>
<td>$48.0</td>
<td>$49.1</td>
<td>$320.00</td>
<td>$216.0K</td>
<td align="right">344</td>
<td align="right">44</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$50.5</td>
<td>$48.55</td>
<td>$49.84</td>
<td>$300.00</td>
<td>$149.1K</td>
<td align="right">158</td>
<td align="right">30</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$48.5</td>
<td>$47.85</td>
<td>$48.5</td>
<td>$300.00</td>
<td>$145.5K</td>
<td align="right">158</td>
<td align="right">61</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$3.6</td>
<td>$3.4</td>
<td>$3.6</td>
<td>$292.50</td>
<td>$63.3K</td>
<td align="right">62</td>
<td align="right">245</td>
</tr>
</tbody>
</table>

<h3>About American Express</h3>
American Express is a global financial institution, operating in about 130 countries, that provides consumers and businesses charge and credit card payment products. The company also operates a highly profitable merchant payment network. Since 2018, it has operated in three segments: global consumer services, global commercial services, and global merchant and network services. In addition to payment products, the company's commercial business offers expense management tools, consulting services, and business loans.
<h3>American Express's Current Market Status</h3>
<ul>
<li>With a volume of 1,303,596, the price of AXP is down -0.22% at $294.87. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 51 days.</li>
</ul>
<h3>Professional Analyst Ratings for American Express</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $331.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from RBC Capital persists with their Outperform rating on American Express, maintaining a target price of $350. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on American Express, maintaining a target price of $370. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for American Express, targeting a price of $320. 
&#x2A; Consistent in their evaluation, an analyst from Compass Point keeps a Neutral rating on American Express with a target price of $309. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on American Express with a target price of $310. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest American Express options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

American Express Options Trading: A Deep Dive into Market Sentiment

As of Feb. 25, 2025, three stocks in the materials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the<a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">ReTo Eco-Solutions Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RETO#NASDAQ">RETO</a>)</h3>
<ul>
<li>On Feb. 4, ReTo announced the receipt of Nasdaq delisting determination. The company's stock gained around 158% over the past five days and has a <a href="https://www.benzinga.com/quote/RETO">52-week high of $3.90</a>.</li>
<li>RSI Value: 72.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>RETO Price Action: Shares of ReTo Eco-Solutions gained 74.6% to trade at $1.03 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Ecolab Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>)</h3>
<ul>
<li>On Feb. 11, Ecolab reported fourth-quarter sales growth of 2% year-on-year to $4.005 billion, beating the consensus estimate of $3.99 billion. Christophe Beck, Ecolab's chairman and chief executive officer, said, "We enter 2025 confident in our ability to deliver continued strong performance in a dynamic environment. Growth in the United States, our largest and most profitable region, continues to be very strong, and growth across the rest of the world is solid as we more than offset uneven macroeconomic trends." The company's stock gained around 9% over the past month and<a href="https://www.benzinga.com/quote/ECL"> has a 52-week high</a> of $268.16.</li>
<li>RSI Value: 70.3</li>
<li>ECL Price Action: Shares of Ecolab gained 1.5% to trade at $267.80 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Pactiv Evergreen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTVE#NASDAQ">PTVE</a>)</h3>
<ul>
<li>On Jan. 21, Pactiv Evergreen announced the expiration of HSR Act waiting period for acquisition by Novolex at $18 per share. The company's stock gained around 52% over the past six months and has a<a href="https://www.benzinga.com/quote/PTVE"> 52-week high</a> of $17.86.</li>
<li>RSI Value: 74</li>
<li>PTVE Price Action: Shares of Pactiv Evergreen gained 0.1% to trade at $17.84 on Tuesday. </li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43937701/how-to-earn-500-a-month-from-lowes-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Lowe&#8217;s Stock Ahead Of Q4 Earnings</a></li>
</ul>

Short Ideas

PTVE

RETO

Top 3 Materials Stocks That May Keep You Up At Night In February

Cantaloupe Shares Halted On Circuit Breaker To The Upside, Stock Now Up 9.76%

Deep-pocketed investors have adopted a bullish approach towards Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in REGN usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 16 extraordinary options activities for Regeneron Pharmaceuticals. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable options, 2 are puts, totaling $104,155, and 14 are calls, amounting to $721,715.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $460.0 to $1000.0 for Regeneron Pharmaceuticals during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Regeneron Pharmaceuticals stands at 49.46, with a total volume reaching 223.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Regeneron Pharmaceuticals, situated within the strike price corridor from $460.0 to $1000.0, throughout the last 30 days.
<h3>Regeneron Pharmaceuticals Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740510946_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$295.0</td>
<td>$290.0</td>
<td>$295.0</td>
<td>$460.00</td>
<td>$147.5K</td>
<td align="right">15</td>
<td align="right">0</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$57.8</td>
<td>$53.0</td>
<td>$53.0</td>
<td>$750.00</td>
<td>$79.5K</td>
<td align="right">127</td>
<td align="right">21</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$79.0</td>
<td>$76.0</td>
<td>$79.0</td>
<td>$950.00</td>
<td>$71.1K</td>
<td align="right">21</td>
<td align="right">9</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$143.7</td>
<td>$135.4</td>
<td>$140.51</td>
<td>$850.00</td>
<td>$70.2K</td>
<td align="right">51</td>
<td align="right">5</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$131.0</td>
<td>$123.0</td>
<td>$126.83</td>
<td>$700.00</td>
<td>$63.4K</td>
<td align="right">46</td>
<td align="right">5</td>
</tr>
</tbody>
</table>

<h3>About Regeneron Pharmaceuticals</h3>
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Having examined the options trading patterns of Regeneron Pharmaceuticals, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Regeneron Pharmaceuticals</h3>
<ul>
<li>With a trading volume of 578,077, the price of REGN is up by 1.55%, reaching $724.34.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 65 days from now.</li>
</ul>
<h3>What The Experts Say On Regeneron Pharmaceuticals</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $839.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Regeneron Pharmaceuticals, maintaining a target price of $1013. 
&#x2A; An analyst from Baird has decided to maintain their Neutral rating on Regeneron Pharmaceuticals, which currently sits at a price target of $759. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for Regeneron Pharmaceuticals, targeting a price of $750. 
&#x2A; In a positive move, an analyst from Leerink Partners has upgraded their rating to Outperform and adjusted the price target to $834. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Regeneron Pharmaceuticals with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

REGN

Regeneron Pharmaceuticals Unusual Options Activity For February 25

Hims &amp; Hers Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares dropped sharply after the company reported its <a href="https://www.benzinga.com/25/02/43941671/hims-hers-health-stock-is-plunging-tuesday-whats-going-on">fourth-quarter earnings.</a> 
What To Know: Hims &amp; Hers posted fourth-quarter earnings of 11 cents per share, matching analyst estimates. Revenue came in at $481.14 million, beating the consensus estimate of $470.31 million and nearly doubling the $246.62 million reported in the same quarter last year. The company's subscriber base grew to 2.2 million, a 45% increase year-over-year but its gross margin dropped to 77% from 83% in fourth-quarter 2023.
Despite the stock&#8217;s decline, Needham analyst Ryan MacDonald reiterated a Buy rating and raised his price target to $61. He pointed to strong fourth-quarter results and a promising outlook for 2025, driven by growth in the company's weight-loss business. MacDonald acknowledged that Hims &amp; Hers shares had sold off after the FDA announced the end of a semaglutide shortage, which could impact short-term revenue from weight-loss treatments. However, he expects the company to generate $725 million from its weight-loss segment in 2025, up from $225 million in 2024.
MacDonald emphasized that the company's core business remains strong, with online revenue up 98.3% year-over-year. He said subscriber growth and increased average revenue per user (ARPU) indicate long-term potential, especially as Hims &amp; Hers expands its multi-condition treatment offerings. Management expects approximately 30% of its 2025 revenue to come from the weight-loss business, up from 15% in 2024 and will discontinue commercially available semaglutide products after the first quarter.
Hims &amp; Hers provided a full-year 2025 revenue forecast of $2.3 billion to $2.4 billion, representing 59.2% growth at the midpoint. Adjusted EBITDA guidance came in at $270 million to $320 million, with margins projected between 12% and 13%. MacDonald's updated price target values Hims &amp; Hers at an enterprise value-to-sales multiple of 6.5 times his 2025 estimates.
HIMS Price Action: Hims &amp; Hers Health shares are down 21.6% at $40.10 at the time of writing, according to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072924&amp;t=be2bearmibe3na1">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="534" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25125601/Screenshot-2025-02-25-at-12.55.12-1024x534.png" alt="" class="wp-image-798088" style="width:473px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25125601/Screenshot-2025-02-25-at-12.55.12-1024x534.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25125601/Screenshot-2025-02-25-at-12.55.12-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25125601/Screenshot-2025-02-25-at-12.55.12-768x401.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25125601/Screenshot-2025-02-25-at-12.55.12.png 1506w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/02/43950022/t-mobile-spotlights-siyatas-sd7-ultra-as-it-reinforces-support-for-first-responders">T-Mobile Spotlights Siyata&#8217;s SD7 Ultra As It Reinforces Support For First Responders</a></li>
</ul>
Image Via Shutterstock.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health Analyst Sees Buying Opportunity Following Steep Selloff: 'We See No Reason To Change Our View'

QCOM

Verizon Collaborates To Samsung And Qualcomm Technologies To Deploy Multi-Vendor Ran Intelligent Controller Functionality In Its Commercial Network

On Tuesday, Plug Power, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) confirmed that its new 15-ton-per-day hydrogen plant in St. Gabriel, Louisiana, is on track <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43936662/plug-powers-louisiana-hydrogen-plant-set-for-first-quarter-operations-with-robust-safety-standards" rel="noreferrer noopener">for its first-quarter operations</a>.
The facility, a joint venture between Plug Power and Olin Corporation, uses Olin&#8217;s by-product hydrogen from chlorine production and will be a key addition to Plug&#8217;s expanding North American hydrogen network.
The project is progressing steadily with a strong focus on safety, having achieved over 412,000 safe working hours with zero recordable injuries.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/02/43941987/why-wah-fu-education-group-wafu-stock-is-surging" rel="noreferrer noopener">Why Wah Fu Education Group Stock Is Surging</a>
Plug Power CEO Andy Marsh highlighted the team&#8217;s success in completing high-risk tasks without incidents, thanks to rigorous safety standards.
The plant is currently undergoing a critical dry-out process to remove moisture and impurities from the piping, vessels, and mechanical systems, ensuring high-purity hydrogen production.
Once operational, the plant will boost Plug Power&#8217;s total hydrogen production capacity to 39 TPD, supporting growing demand from major partners like Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>).
With operations slated to begin in the first quarter, the St. Gabriel plant will strengthen Plug Power&#8217;s position as a leader in vertically integrated hydrogen solutions, providing more sustainable and reliable energy alternatives.
Plug Power will report fourth-quarter <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43936213/plug-to-announce-2024-fourth-quarter-and-year-end-results" rel="noreferrer noopener">results on Monday, March 3, 2025.</a>
Price Action: PLUG shares are trading lower by 0.31% to $1.585 at the last check on Tuesday.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43937535/home-depot-lifts-annual-dividend-after-strong-q4-but-soft-2025-outlook-weighs-on-stock" target="_blank" rel="noreferrer noopener">Home Depot Lifts Annual Dividend After Strong Q4, But Soft 2025 Outlook Weighs On Stock</a></li>
</ul>
Photo courtesy of Plug Power

Equities

AMZN

PLUG

What's Going On With Plug Power Stock On Tuesday?

Press Releases

Ryan Specialty in Final Discussions to Acquire Innovisk Capital Partners

Ryan Specialty Reports Third Quarter 2024 Results

Insurance

Abry Partners and BHMS Announce Sale of Innovisk to Ryan Specialty

Ryan Specialty Completes Acquisition of Innovisk Capital Partners

Ryan Specialty, LLC Launches Private Offering of $500 Million of Senior Secured Notes

Ryan Specialty, LLC Upsizes and Prices $600 Million of Senior Secured Notes

Ryan Specialty Signs Definitive Agreement to Acquire Velocity Risk Underwriters

Ryan Specialty to Announce Fourth Quarter 2024 Financial Results on Thursday, February 20, 2025

Ryan Specialty Completes Acquisition of Velocity Risk Underwriters

Ryan Specialty Reports Fourth Quarter 2024 Results

RYAN

Abacus Life

Arthur J. Gallagher

Aon plc Class A Ordinary Shares (Ireland)

Brown & Brown

The Baldwin Insurance Group, Inc. - Class A Common Stock

Baldwin Insurance

Cheche Group Inc. - Class A Ordinary Shares

Cheche Group

Crawford & Company Common Stock

eHealth

GoHealth

Goosehead Insurance, Inc. - Class A Common Stock

Goosehead Insurance

Hagerty

Hippo Holdings

Health In Tech, Inc. - Class A Common Stock

Health In Tech

Huize Holding Limited - American Depositary Shares

Huize Holding

Marsh & McLennan Companies, Inc. Common Stock

Marsh & McLennan

Reliance Global Group, Inc. - Common Stock

Reliance Global Group

SelectQuote

TIAN RUIXIANG Holdings Ltd - Class A Ordinary Shares

Tian Ruixiang Holdings

TWFG

Waterdrop Inc. American Depositary Shares (each representing the right to receive 10 Class A Ordinary Shares)

Comments

Ryan Specialty Hldgs

ニュース

最新ニュース Ryan Specialty Hldgs (NYSE:RYAN) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル